Cardioselectivity Studies
by Dr M K Benson (St Mary's Hospital, Portsmouth) One of the predictable and widely recognized unwanted effects of beta blockade is to precipitate bronchospasm in patients with asthma, and since both asthma and hypertension are relatively common clinical conditions, inevitably the two not infrequently coexist.
This paper describes a study performed in Southampton with Dr Graham Sterling to compare the effects of four beta blockers on the airways function in patients with asthma. A population of 14 asthmatic patients was initially selected from our outpatient clinic, but one subsequently withdrew for personal reasons in the middle of the study. The age range was 17 to 64 years. All patients had a history of episodic dyspncea and wheeze and in addition documented evidence of significant spontaneous variation in their FEV1. Most of the patients were in clinical remission, and for ethical reasons patients with severe bronchospasm were not included in the study. The drugs selected were two noncardioselective (propranolol and pindolol) and two cardioselective (acebutolol and atenolol), one of each pair (propranolol and atenolol) having no agonist (ISA) activity. The doses were 100 mg propranolol, 5 mg pindolol, 300 mg acebutolol and 100 mg atenolol together with placebo. This sort of study using single dose regimes has obvious limitations and the dosage was selected according to generally accepted potency ratio and to bear some relevance to clinical prescribing habits. The drugs were coded and given in a randomized order, on each of five occasions. Over an initial half-hour period, baseline measurements of resting heart rate, blood pressure, forced vital capacity, forced expiratory volume in one second, and peak expiratory flow rate were measured. The drugs were then given and measurements repeated half-hourly over the next two hours. At the end of this time a therapeutic dose of isoprenaline sulphate (1200 ,ug from a Medihaler-Iso) was given and airways and cardiovascular responses remeasured.
Changes in pulse rate are shown in Table 1 . There was a significant reduction in resting pulse rate following all drugs including placebo, although the fall was significantly greater for propranolol and atenolol. Following the placebo period, isoprenaline produced an increase in heart rate which was blocked by all four active drugs. All patients were initially normotensive and although there were small changes in blood pressure these were not significant for any of the drugs.
There was a wide range of response both between the drugs and between patients in terms of airway response. Thus, following propranolol responses ranged from no significant change to severe bronchospasm in one patient whose FEV1 fell from 2.0 1 to 0.3 1 and who was subsequently withdrawn from further study. The remaining patients could be divided into two groups (Table  1 ). There were seven patients who showed no significant constrictor response to any of the beta blockers and five who showed significant bronchospasm following at least one of the drugs. In general the responders had a lower mean FEV1 under control conditions than the nonresponders. This division is an arbitrary one applicable only to these patients at the time of study. The difference in response may be a reflection of the isoprenaline was blocked by propranolol and pindolol but not by acebutolol and atenolol.
Four of these patients were given two further beta blockers, metoprolol and oxprenolol (Fig 3) . Metoprolol behaved very much like acebutolol in causing a small constrictor response but permitting a bronchodilator response whereas oxprenolol caused a large constrictor response which did not improve after isoprenaline.
Conclusions
(1) Some patients with asthma, especially those in clinical remission, showed no significant constrictor response to beta blockade.
(2) The property of cardioselectivity is a relative one. Of the drugs studied, propranolol produced the most and atenolol the least bronchoconstriction.
(3) Both atenolol and acebutolol permitted a bronchodilator response to a conventional therapeutic dose of inhaled isoprenaline.
